| [November 20, 2018] |
 |
Pear Therapeutics to Participate in Evercore ISI HEALTHCONx Conference
Pear
Therapeutics, Inc., the leader in prescription digital therapeutics,
today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief
Financial Officer and Chief Operating Officer, will participate in a
digital therapeutics panel discussion at the Evercore ISI (News - Alert) HEALTHCONx
Conference on Wednesday, November 28 at 6:00 p.m. at the Boston Harbor
Hotel.
Pear Therapeutics is a privately held, prescription digital therapeutics
company developing clinically validated, FDA-authorized software
applications to treat serious disease.
p>
About Pear Therapeutics
Pear Therapeutics is the
leader in prescription digital therapeutics. We aim to redefine medicine
by discovering, developing, and delivering clinically validated
software-based therapeutics to provide better outcomes for patients,
smarter engagement and tracking tools for clinicians, and cost-effective
solutions for payers. Pear has a pipeline of
products and product candidates across therapeutic areas,
including mental health disorders, severe insomnia, and
multiple sclerosis. Our lead product, reSET®, treats Substance
Use Disorder (SUD) and was the first prescription digital therapeutic to
receive marketing authorization from the FDA to treat disease. Pear's
second product, reSET-O™, for the treatment of Opioid Use Disorder
(OUD), is currently under FDA review with Breakthrough Designation. For
more information, visit us at www.peartherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005019/en/
[ Back To TMCnet.com's Homepage ]
|
